FOXM 1 Expression in Breast Carcinoma and Correlation with Histopathological Staging and Grading

Rafah Mohamed Jaffar Alkhateeb; Salim Rasheed Alaubaidy

doi:doi:10.11648/j.plm.20180201.13

| Peer-Reviewed

FOXM 1 Expression in Breast Carcinoma and Correlation with Histopathological Staging and Grading

Rafah Mohamed Jaffar Alkhateeb, Salim Rasheed Alaubaidy

Published in Pathology and Laboratory Medicine (Volume 2, Issue 1)

Received: 13 March 2018 Accepted: 11 April 2018 Published: 17 May 2018

Views: Downloads:

Download PDF

Share This Article

Twitter
Linked In
Facebook

Abstract

FOXM1 (Forkhead box protein M1) promoted EMT (Epithelial-to-mesenchymal transition) in breast cancer by binding and activation of the promoter of SLUG gene. that FOXM1 promotes breast cancer metastases by activation of the TGF-β pathway with through interaction SMAD3 (this prevented E3 ubiquitin-protein ligase transcriptional intermediary factor 1 γ [TIF1 γ] binding to SMAD3 and protected SMAD4 from ubiquitination) that leads to stabilization of the SMAD3/SMAD4 complex. The study samples included seventy four formalin-fixed, paraffin embedded tissue blocks which have been diagnosed as forty four cases of breast carcinoma and their lymph nodes. In the present study from 74 total cases, 46 cases (62.6%) were showing FOXM1 marker positive while 28 cases (37.8%) were showing negative immunohistochemistry for FOXM1 marker. Sub classification of malignant cases, 16 malignant breast cancer cases (36.4%) showed no FOXM1 expression, while 12 malignant cases (27.3%) were strongly positive for FOXM1 expression. There is significant correlation between breast carcinoma grade, stage and FOXM1 expression.

Published in	Pathology and Laboratory Medicine (Volume 2, Issue 1)
DOI	10.11648/j.plm.20180201.13
Page(s)	15-19
Creative Commons	This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.
Copyright	Copyright © The Author(s), 2024. Published by Science Publishing Group

Keywords

Breast Tumor, Breast Cancer, FOXM1 Expression

References

[1]	Susan G. Komen. What is breast cancer? Fact for life. 2016; 2/16.
[2]	Takahashi R, Takeshita F, Fujiwara T, Ono M, Ochiya T. Cancer stem cells in breast cancer. Cancers 2011; 3: 1311-1328.
[3]	Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CHM, Jones DL, Visvader J, Weissman IL, Wahl GM. Cancer StemCells-Perspectives on Current Status and Future Directions:AACR Workshop on Cancer Stem Cells. Cancer Res 2006; 66: 9339-9344.
[4]	Chan SW, Lim CJ, Guo K, Ng CP, Lee I, Hunziker W, Zeng Q, Hong W. A role for TAZ in migration, invasion, and tumorigenesis of breast cancer cells. Cancer Res. Apr. 2008; 68 (8):2592–2598.
[5]	Ye H, Kelly TF, Samadani U, Lim L, Rubio S, Overdier DG, Roebuck KA, Costa RH. "Hepatocyte nuclear factor 3/fork head homolog 11 is expressed in proliferating epithelial and mesenchymal cells of embryonic and adult tissues". Mol. Cell. Biol. 1997; 17 (3): 1626–41.
[6]	Vincent Shen. "2010 Molecule of the Year". BioTechniques.
[7]	Laoukili J, Kooistra MR, Brás A, Kauw J, Kerkhoven RM, Morrison A, Clevers H, Medema RH. FoxM1 is required for execution of the mitotic programme and chromosome stability. Nat. Cell Biol. 2005; 7 (2): 126–36.
[8]	Pilarsky, C., Wenzig, M., Specht, T., Saeger, H. D., and Grutzmann, R. Identification and validation of commonly overexpressed genes in solid tumors by comparison of microarray data. Neoplasia. 2004; 6, 744–750.
[9]	Nakamura, S., Hirano, I., Okinaka, K., Takemura, T., Yokota, D., Ono, T., et al. The FOXM1 transcriptional factor promotes the proliferation of leukemia cells through modulation of cell cycle progression in acute myeloid leukemia. Carcinogenesis. 2010; 31, 2012–2021.
[10]	Kwok, J. M., Peck, B., Monteiro, L. J., Schwenen, H. D., Millour, J., Coombes, R. C., et al. FOXM1 confers acquired cisplatin resistance in breast cancer cells. Mol. Cancer Res. 2010; 8, 24–34.
[11]	Zhang, N., Wu, X., Yang, L., Xiao, F., Zhang, H., Zhou, A., et al. FoxM1 inhibition sensitizes resistant glioblastoma cells to temozolomide by downregulating the expression of DNA-repair gene Rad51. Clin. Cancer Res. 2010a; 18, 5961–5971.
[12]	Halasi, M., and Gartel, A. L. Suppression of FOXM1 sensitizes human cancer cells to cell death induced by DNA-damage. PLoS ONE. 2012a; 7:e31761.
[13]	Xue, W., Zender, L., Miething, C., Dickins, R. A., Hernando, E., Krizhanovsky, V., et al. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature. 2007;-445, 656–660.
[14]	Radhakrishnan, S. K., Bhat, U. G., Hughes, D. E., Wang, I. C., Costa, R. H., and Gartel, A. L. Identification of a chemical inhibitor of the oncogenic transcription factor forkhead box M1. Cancer Res. 2006; 66, 9731–9735.
[15]	Myatt, S. S., and Lam, E. W. The emerging roles of forkhead box (Fox) proteins in cancer. Nat. Rev. Cancer. 2007; 7, 847–859.
[16]	Pilarsky, C., Wenzig, M., Specht, T., Saeger, H. D., and Grutzmann, R. Identification and validation of commonly overexpressed genes in solid tumors by comparison of microarray data. Neoplasia. 2004; 6, 744–750.
[17]	Wonsey DR, Follettie MT. "Loss of the forkhead transcription factor FoxM1 causes centrosome amplification and mitotic catastrophe". Cancer Res. 2005; 65 (12): 5181–9.
[18]	C. Yang, H. Chen, G. Tan et al., “FOXM1 promotes the epithelial to mesenchymal transition by stimulating the transcription of Slug in human breast cancer,” Cancer Letters. 2013; vol. 340, no. 1, pp. 104–112.
[19]	J. Xue, X. Lin, W.-T. Chiu et al., “Sustained activation of SMAD3/SMAD4 by FOXM1 promotes TGF-β-dependent cancer metastasis,” The Journal of Clinical Investigation. 2014; vol. 124, no. 2, pp. 564–579.
[20]	J. Laoukili, M. Alvarez Fernandez, R. H Medema." FOXM1 (forkhead box M1)", Atlas of Genetics and Cytogenetics in Oncology and Haematology, 2008-2.
[21]	Jeong-Ju Lee, Hee Jin Lee, Byung-Ho Son, Sung-Bae Kim, Jin-Hee Ahn, Seung Do Ahn, Eun Yoon Cho and Gyungyub Gong. Expression of FOXM1 and related proteins in breast cancer molecular subtypes. INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY. 2016; 97, 170–177.
[22]	Jing zhang, kundong zhang, lisheng zhou, weidong wu, tao jun cao, kejian huang, zhengjun qiu and chen huang. Expression and potential correlation among Forkhead box protein M1, Caveolin‑1 and E‑cadherin in colorectal cancer. ONCOLOGY LETTERS. 2016; 12; 2381-2388.

Cite This Article

Plain Text BibTeX RIS

APA Style

Rafah Mohamed Jaffar Alkhateeb, Salim Rasheed Alaubaidy. (2018). FOXM 1 Expression in Breast Carcinoma and Correlation with Histopathological Staging and Grading. Pathology and Laboratory Medicine, 2(1), 15-19. https://doi.org/10.11648/j.plm.20180201.13

Copy | Download

ACS Style

Rafah Mohamed Jaffar Alkhateeb; Salim Rasheed Alaubaidy. FOXM 1 Expression in Breast Carcinoma and Correlation with Histopathological Staging and Grading. Pathol. Lab. Med. 2018, 2(1), 15-19. doi: 10.11648/j.plm.20180201.13

Copy | Download

AMA Style

Rafah Mohamed Jaffar Alkhateeb, Salim Rasheed Alaubaidy. FOXM 1 Expression in Breast Carcinoma and Correlation with Histopathological Staging and Grading. Pathol Lab Med. 2018;2(1):15-19. doi: 10.11648/j.plm.20180201.13

Copy | Download

@article{10.11648/j.plm.20180201.13,
  author = {Rafah Mohamed Jaffar Alkhateeb and Salim Rasheed Alaubaidy},
  title = {FOXM 1 Expression in Breast Carcinoma and Correlation with Histopathological Staging and Grading},
  journal = {Pathology and Laboratory Medicine},
  volume = {2},
  number = {1},
  pages = {15-19},
  doi = {10.11648/j.plm.20180201.13},
  url = {https://doi.org/10.11648/j.plm.20180201.13},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.plm.20180201.13},
  abstract = {FOXM1 (Forkhead box protein M1) promoted EMT (Epithelial-to-mesenchymal transition) in breast cancer by binding and activation of the promoter of SLUG gene. that FOXM1 promotes breast cancer metastases by activation of the TGF-β pathway with through interaction SMAD3 (this prevented E3 ubiquitin-protein ligase transcriptional intermediary factor 1 γ [TIF1 γ] binding to SMAD3 and protected SMAD4 from ubiquitination) that leads to stabilization of the SMAD3/SMAD4 complex. The study samples included seventy four formalin-fixed, paraffin embedded tissue blocks which have been diagnosed as forty four cases of breast carcinoma and their lymph nodes. In the present study from 74 total cases, 46 cases (62.6%) were showing FOXM1 marker positive while 28 cases (37.8%) were showing negative immunohistochemistry for FOXM1 marker. Sub classification of malignant cases, 16 malignant breast cancer cases (36.4%) showed no FOXM1 expression, while 12 malignant cases (27.3%) were strongly positive for FOXM1 expression. There is significant correlation between breast carcinoma grade, stage and FOXM1 expression.},
 year = {2018}
}

Copy | Download

TY  - JOUR
T1  - FOXM 1 Expression in Breast Carcinoma and Correlation with Histopathological Staging and Grading
AU  - Rafah Mohamed Jaffar Alkhateeb
AU  - Salim Rasheed Alaubaidy
Y1  - 2018/05/17
PY  - 2018
N1  - https://doi.org/10.11648/j.plm.20180201.13
DO  - 10.11648/j.plm.20180201.13
T2  - Pathology and Laboratory Medicine
JF  - Pathology and Laboratory Medicine
JO  - Pathology and Laboratory Medicine
SP  - 15
EP  - 19
PB  - Science Publishing Group
SN  - 2640-4478
UR  - https://doi.org/10.11648/j.plm.20180201.13
AB  - FOXM1 (Forkhead box protein M1) promoted EMT (Epithelial-to-mesenchymal transition) in breast cancer by binding and activation of the promoter of SLUG gene. that FOXM1 promotes breast cancer metastases by activation of the TGF-β pathway with through interaction SMAD3 (this prevented E3 ubiquitin-protein ligase transcriptional intermediary factor 1 γ [TIF1 γ] binding to SMAD3 and protected SMAD4 from ubiquitination) that leads to stabilization of the SMAD3/SMAD4 complex. The study samples included seventy four formalin-fixed, paraffin embedded tissue blocks which have been diagnosed as forty four cases of breast carcinoma and their lymph nodes. In the present study from 74 total cases, 46 cases (62.6%) were showing FOXM1 marker positive while 28 cases (37.8%) were showing negative immunohistochemistry for FOXM1 marker. Sub classification of malignant cases, 16 malignant breast cancer cases (36.4%) showed no FOXM1 expression, while 12 malignant cases (27.3%) were strongly positive for FOXM1 expression. There is significant correlation between breast carcinoma grade, stage and FOXM1 expression.
VL  - 2
IS  - 1
ER  -

Copy | Download

Author Information

Rafah Mohamed Jaffar Alkhateeb

Imamain Kadhymien Teaching Hospital, Baghdad, Iraq
Salim Rasheed Alaubaidy

Pathology Department & Forensic Medicine, College of Medicine/University of Baghdad, Baghdad, Iraq

Download PDF

Sections

Plain Text BibTeX RIS

APA Style

Rafah Mohamed Jaffar Alkhateeb, Salim Rasheed Alaubaidy. (2018). FOXM 1 Expression in Breast Carcinoma and Correlation with Histopathological Staging and Grading. Pathology and Laboratory Medicine, 2(1), 15-19. https://doi.org/10.11648/j.plm.20180201.13

Copy | Download

ACS Style

Rafah Mohamed Jaffar Alkhateeb; Salim Rasheed Alaubaidy. FOXM 1 Expression in Breast Carcinoma and Correlation with Histopathological Staging and Grading. Pathol. Lab. Med. 2018, 2(1), 15-19. doi: 10.11648/j.plm.20180201.13

Copy | Download

AMA Style

Rafah Mohamed Jaffar Alkhateeb, Salim Rasheed Alaubaidy. FOXM 1 Expression in Breast Carcinoma and Correlation with Histopathological Staging and Grading. Pathol Lab Med. 2018;2(1):15-19. doi: 10.11648/j.plm.20180201.13

Copy | Download

@article{10.11648/j.plm.20180201.13,
  author = {Rafah Mohamed Jaffar Alkhateeb and Salim Rasheed Alaubaidy},
  title = {FOXM 1 Expression in Breast Carcinoma and Correlation with Histopathological Staging and Grading},
  journal = {Pathology and Laboratory Medicine},
  volume = {2},
  number = {1},
  pages = {15-19},
  doi = {10.11648/j.plm.20180201.13},
  url = {https://doi.org/10.11648/j.plm.20180201.13},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.plm.20180201.13},
  abstract = {FOXM1 (Forkhead box protein M1) promoted EMT (Epithelial-to-mesenchymal transition) in breast cancer by binding and activation of the promoter of SLUG gene. that FOXM1 promotes breast cancer metastases by activation of the TGF-β pathway with through interaction SMAD3 (this prevented E3 ubiquitin-protein ligase transcriptional intermediary factor 1 γ [TIF1 γ] binding to SMAD3 and protected SMAD4 from ubiquitination) that leads to stabilization of the SMAD3/SMAD4 complex. The study samples included seventy four formalin-fixed, paraffin embedded tissue blocks which have been diagnosed as forty four cases of breast carcinoma and their lymph nodes. In the present study from 74 total cases, 46 cases (62.6%) were showing FOXM1 marker positive while 28 cases (37.8%) were showing negative immunohistochemistry for FOXM1 marker. Sub classification of malignant cases, 16 malignant breast cancer cases (36.4%) showed no FOXM1 expression, while 12 malignant cases (27.3%) were strongly positive for FOXM1 expression. There is significant correlation between breast carcinoma grade, stage and FOXM1 expression.},
 year = {2018}
}

Copy | Download

TY  - JOUR
T1  - FOXM 1 Expression in Breast Carcinoma and Correlation with Histopathological Staging and Grading
AU  - Rafah Mohamed Jaffar Alkhateeb
AU  - Salim Rasheed Alaubaidy
Y1  - 2018/05/17
PY  - 2018
N1  - https://doi.org/10.11648/j.plm.20180201.13
DO  - 10.11648/j.plm.20180201.13
T2  - Pathology and Laboratory Medicine
JF  - Pathology and Laboratory Medicine
JO  - Pathology and Laboratory Medicine
SP  - 15
EP  - 19
PB  - Science Publishing Group
SN  - 2640-4478
UR  - https://doi.org/10.11648/j.plm.20180201.13
AB  - FOXM1 (Forkhead box protein M1) promoted EMT (Epithelial-to-mesenchymal transition) in breast cancer by binding and activation of the promoter of SLUG gene. that FOXM1 promotes breast cancer metastases by activation of the TGF-β pathway with through interaction SMAD3 (this prevented E3 ubiquitin-protein ligase transcriptional intermediary factor 1 γ [TIF1 γ] binding to SMAD3 and protected SMAD4 from ubiquitination) that leads to stabilization of the SMAD3/SMAD4 complex. The study samples included seventy four formalin-fixed, paraffin embedded tissue blocks which have been diagnosed as forty four cases of breast carcinoma and their lymph nodes. In the present study from 74 total cases, 46 cases (62.6%) were showing FOXM1 marker positive while 28 cases (37.8%) were showing negative immunohistochemistry for FOXM1 marker. Sub classification of malignant cases, 16 malignant breast cancer cases (36.4%) showed no FOXM1 expression, while 12 malignant cases (27.3%) were strongly positive for FOXM1 expression. There is significant correlation between breast carcinoma grade, stage and FOXM1 expression.
VL  - 2
IS  - 1
ER  -

Copy | Download